Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Business Wire - Mon Jun 8, 5:59AM CDT

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions ...

BMY : 56.90 (+2.34%)
ICFI
3 Value Stocks We Think Twice About StockStory - Wed Jun 3, 11:39PM CDT

3 Value Stocks We Think Twice About

MTG : 25.47 (-0.97%)
ICFI : 72.49 (+1.26%)
BMY : 56.90 (+2.34%)
Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock
Is Bristol-Myers Squibb Stock Underperforming the Dow? Barchart - Tue Jun 2, 10:48PM CDT

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

LLY : 1,160.95 (+2.16%)
$DOWI : 50,848.75 (+1.86%)
BMY : 56.90 (+2.34%)
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma Business Wire - Tue Jun 2, 7:00AM CDT

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO ® 2026 ...

BMY : 56.90 (+2.34%)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Business Wire - Mon Jun 1, 5:59AM CDT

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population ...

BMY : 56.90 (+2.34%)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Business Wire - Mon Jun 1, 5:55AM CDT

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL)

BMY : 56.90 (+2.34%)
BMY
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1 StockStory - Sun May 31, 10:31PM CDT

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

BMY : 56.90 (+2.34%)
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma Business Wire - Fri May 29, 7:00AM CDT

First Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO ® 2026 SUCCESSOR-2 data reinforce...

BMY : 56.90 (+2.34%)
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire - Wed May 27, 5:59AM CDT

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026. ...

BMY : 56.90 (+2.34%)
VSH
1 Surging Stock with Promising Prospects and 2 We Ignore StockStory - Sun May 24, 11:37PM CDT

1 Surging Stock with Promising Prospects and 2 We Ignore

KO : 82.53 (-1.27%)
VSH : 58.60 (+7.23%)
BMY : 56.90 (+2.34%)

Barchart Exclusives

Virgin Galactic Stock Leads Space Stocks Higher Ahead of SpaceX IPO Barchart - 1 hour ago
Virgin Galactic stock is a wave of SpaceX IPO momentum sweeps through the sector. But is it already too late to invest in SPCE shares now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.